imx-110
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2018 (NCT03382340)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05840835 | Phase 1/Phase 2 (Phase 2) | Feb 3, 2023 | BeOne Medicines, Immix Biopharma Australia Pty Ltd, Novartis |
| NCT03382340 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2018 | Immix Biopharma Australia Pty Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immix Biopharma Australia Pty Ltd | For profit | 2 | 2 | 1 | 2018 |
| BeOne Medicines | For profit | 1 | 0 | 1 | 2023 |
| Novartis | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1